Site Editors
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Posted: Friday, September 30, 2022
Rakesh Popat, MBBS, PhD, of University College London Hospitals NHS Foundation Trust, United Kingdom, and colleagues evaluated the potential correlation between treatment duration of belantamab mafodotin-blmf, baseline ocular conditions, and other residual ocular symptoms in patients with relapsed or refractory multiple myeloma. Presented during the 2022 International Myeloma Society (IMS) Annual Meeting and Exposition (Abstract OAB-049), the results of this study suggest that patients with cornea-related baseline ocular conditions alone may be more likely to develop further ocular symptoms while on treatment with the monoclonal antibody.
“There was little evidence that other baseline ocular conditions, such as cataract, glaucoma, or blepharitis, had any effect on treatment-emergent ocular symptoms,” mentioned the study authors. “These findings inform risk/benefit decision-making with belantamab mafodotin and indicate that belantamab mafodotin can be a treatment option for patients with relapsed or refractory multiple myeloma despite baseline ocular conditions.”
From the DREAMM-2 study (ClinicalTrials.gov identifier NCT03525678), the investigators evaluated 218 patients with relapsed or refractory multiple myeloma who received belantamab mafodotin after more than three lines of therapy. Eye examinations that screened for the most common ocular conditions were performed at baseline and before each treatment dose.
The majority (n = 198) of individuals had baseline ocular conditions, with cataracts (66%), keratopathy (52%), and dry eye (22%) among the most common. Overall, dry eye and blurred vision were the most common ocular symptoms related to treatment with belantamab mafodotin. Of note, there was virtually no variance in ocular symptoms among patients with and without conditions relating to eyelids, the optic nerve, or the lens at baseline.
Blurred vision occurred more frequently in patients with dry eye and those with age-related macular degeneration at baseline. Additionally, there appeared to be no differences in ocular symptoms among patients exposed to belantamab mafodotin for 3 months. However, there was an observed increase in blurred vision among patients with keratopathy and dry eye at baseline.
Disclosure: Disclosure information was not provided.
2022 IMS Annual Meeting and Exposition
JNCCN Spotlights
